In the multicohort, phase 1a/b Beamion LUNG-1 trial, zongertinib demonstrated a high objective response rate and durable responses in treatment-naive patients with advanced HER2-mutant non-small cell lung cancer (NSCLC).1
Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that recently received accelerated approval from the US Food and Drug Administration for previously treated patients with unresectable or metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain-activating mutations.2 The current analysis evaluated its potential role in the first-line setting, where treatment options for patients with HER2-mutant NSCLC have been historically limited.
Brett Bade, MD, pulmonologist and Senior Associate Consultant at Mayo Clinic, and Katie Smith, MD, oncologist and Assistant Professor at Mayo Clinic, said the findings represent another step forward in expanding targeted treatment options for patients with lung cancer.
“In the study at hand, having another option for an effective, oral therapy for metastatic lung cancer is a huge advance,” Dr. Smith said. “In general, we are seeing a steady expansion in the availability of effective, targeted therapies for patients with lung cancer.”
The trial evaluated the efficacy and safety of zongertinib in treatment-naive patients, with 74 patients enrolled in cohort 2 receiving 120 mg of zongertinib once daily.1
The primary end point was confirmed objective response rate (ORR) as assessed by blinded independent central review, while secondary end points included duration of response (DOR) and progression-free survival (PFS).1
Among the enrolled patients, the confirmed ORR was 76% (95% CI, 65-84). Median DOR was 15.2 months (95% CI, 9.8 to not evaluable), and median PFS was 14.4 months (95% CI, 11.1 to not evaluable).1
In the trial, 67 participants experienced treatment-related adverse events, most of which were low-grade; however, 14 patients reported events of grade 3 or higher. While diarrhea and rash were the most frequent side effects, there were few cases of interstitial lung disease—a severe complication often linked to alternative therapies.3
“Due to patient convenience [ie, oral therapy vs IV], fewer side effects, and often greater efficacy, the expansion of targeted therapy options for patients with lung cancer is an exciting advance,” Dr. Bade said.
Despite the encouraging efficacy and safety findings, the physicians noted that important questions remain regarding the role of zongertinib in the first-line treatment setting.
“The main unanswered question is if zongertinib is truly better than the current first-line standard of care, which is platinum-based chemotherapy doublet with immunotherapy, and thankfully, that study is ongoing,” Dr. Smith said.
Drs. Smith and Bade agreed that moving zongertinib into the first-line setting could raise questions about optimal treatment sequencing in later lines of therapy. As targeted therapies become available for additional molecular subtypes of NSCLC, they emphasized the importance of comprehensive molecular testing at diagnosis.
Dr. Smith pointed out that identifying actionable driver mutations can significantly influence treatment decisions and patient outcomes.
“In general, we are witnessing rapid changes in the treatment of lung cancer,” she said. “The better we understand a person’s tumor biology, the better able we are to identify individualized treatment regimens that are better tolerated and more effective.”
References
1. Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;392(23):2321-2333. doi:10.1056/NEJMoa2503704
2. US Food and Drug Administration. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. Published August 8, 2025.
3. University of Texas MD Anderson Cancer Center. First-line targeted therapy shows antitumor activity in patients with advanced lung cancer. Published April 16, 2026. UT MD Anderson Research News.
